A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...

The prevalence of type 2 diabetes is increasing because the population is aging and becoming more obese and more sedentary. Diabetes has become the most common cause of new blindness, end-stage renal ...

A single 68Ga-pentixafor PET/CT scan identified five functional aldosterone-producing adenomas on both adrenal glands, ...

An experimental drug lowered blood pressure and reduced a marker of kidney damage in people with chronic kidney disease. The ...

Unprecedented access to a unique group of Australians is allowing researchers to study links between raised aldosterone levels and elevated cardiovascular risk in various age groups—with important ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Increased levels of aldosterone are independently associated with a greater risk of type 2 diabetes, with the effects particularly notable in certain ethnic groups including African Americans and ...

Aldosterone antagonists (spironolactone, eplerenone) also known as “potassium sparing diuretics” block the action of aldosterone inhibiting the reuptake of sodium and water. Normally, when sodium ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as ...